Back to search results

Study on Tools to Improve Heart Failure Medication Use

This study, called I-I-CAPTAIN-HF, is looking at ways to help people with heart failure with reduced ejection fraction (HFrEF) get the most out of their medications. These medications, called guideline-directed medical therapies (GDMT), can greatly improve heart function and quality of life. The study is testing two tools: the EPIC-HF Patient-facing Tool, which is a video and checklist for patients before their clinic visit, and the PROMPT-HF Clinician-facing Alert, which is an alert for doctors in the patient's medical record. The goal is to see if these tools help more patients receive the recommended GDMT. You may be able to join if you are over 18 and have HFrEF, meaning your heart's pumping ability (LVEF) is 40% or less. The study plans to enroll 2200 participants, but its current status is unclear.

Study design
This is an interventional study that plans to enroll 2200 participants. It is testing two behavioral tools to improve medication use for heart failure.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main goal is measured from before your clinic visit to 1 day after.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06526988

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

Recruiting
NAAges 18+InterventionalHealth services
University of Colorado, Denver
~2,200 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:EPIC-HF Patient-facing ToolPROMPT-HF Clinician-facing Alert

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Intensification of GDMT in patients with Heart Failure with Reduced Ejection Fraction
Measured over From pre-clinic visit to 1 day after

Conditions

Heart Failure With Reduced Ejection Fraction

Explore related trials

Heart failure with reduced ejection fraction

NCT06526988

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Colorado

    Aurora, Coloradostudy coordinator listed

    Recruiting

  • Northwestern University

    Chicago, Illinoisno site contact published

    Recruiting

  • Sutter Health

    Walnut Creek, Californiano site contact published

    Recruiting

  • University of Utah

    Salt Lake City, Utahno site contact published

    Recruiting

  • Yale University

    New Haven, Connecticutno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Larry A Allen, MD, MHS · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Who to contact

Larry A Allen, MD, MHS
[email protected]
303-724-4713
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinician (MD, PA, NP) who practices in cardiology outpatient clinics
Regularly sees patients with left ventricular ejection fraction (EF) \</=40%, where their panel of patients over the last year included at least 10 patients with heart failure with reduced ejection fraction (HFrEF)
Age \> 18 years
LVEF \</=40% on most recent cardiology imaging study
Has a new or return clinic visit with an enrolled clinician within the next 7 days
Is missing at least one of the four classes of medications and does not have an allergy to that class: (1) beta blockers, (2) angiotensin receptor-neprilysin inhibitor, (3) aldosterone receptor antagonists, (4) sodium-glucose co-transporter

Exclusion

Has a left ventricular assist device
Under evaluation for or listed for transplant (or s/p transplant)
Glomerular filtration rate (GFR) less than 20 or on dialysis
On hospice care
Preferred language neither English or Spanish

What this trial measures

  • Intensification of GDMT in patients with Heart Failure with Reduced Ejection FractionFrom pre-clinic visit to 1 day after

    The primary outcome for this trial is the proportion of patients with HFrEF who have an increase in the number of prescribed HFrEF therapies (beta blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) and/or dosing intensification from pre-clinic visit to 1 day after.